Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_3
1
25%
Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_2
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A1 (25.0%)

Trials by Status

active_not_recruiting125%
completed125%
terminated250%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_1

Stem Cell Transplantation for Patients With Multiple Myeloma

NCT01526096
active_not_recruitingphase_3

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

NCT02375204
terminatednot_applicable

Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

NCT00363467
terminatedphase_2

Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors

NCT00851110

Clinical Trials (4)

Showing 4 of 4 trials
NCT01526096Phase 1

Stem Cell Transplantation for Patients With Multiple Myeloma

Completed
NCT02375204Phase 3

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Active Not Recruiting
NCT00363467Not Applicable

Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

Terminated
NCT00851110Phase 2

Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors

Terminated

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4